ATE313803T1 - In vitro screening nach liganden des östrogenrezeptors - Google Patents

In vitro screening nach liganden des östrogenrezeptors

Info

Publication number
ATE313803T1
ATE313803T1 AT01126336T AT01126336T ATE313803T1 AT E313803 T1 ATE313803 T1 AT E313803T1 AT 01126336 T AT01126336 T AT 01126336T AT 01126336 T AT01126336 T AT 01126336T AT E313803 T1 ATE313803 T1 AT E313803T1
Authority
AT
Austria
Prior art keywords
ligand
src
assay system
ligands
vitro screening
Prior art date
Application number
AT01126336T
Other languages
English (en)
Inventor
Vladimir Patchev
Youriy Mitev
Siegmund Wolf
Gernot Langer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of ATE313803T1 publication Critical patent/ATE313803T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01126336T 2001-11-07 2001-11-07 In vitro screening nach liganden des östrogenrezeptors ATE313803T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01126336A EP1310799B1 (de) 2001-11-07 2001-11-07 In vitro Screening nach Liganden des Östrogenrezeptors

Publications (1)

Publication Number Publication Date
ATE313803T1 true ATE313803T1 (de) 2006-01-15

Family

ID=8179169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01126336T ATE313803T1 (de) 2001-11-07 2001-11-07 In vitro screening nach liganden des östrogenrezeptors

Country Status (6)

Country Link
US (1) US7166438B2 (de)
EP (1) EP1310799B1 (de)
JP (1) JP3754647B2 (de)
AT (1) ATE313803T1 (de)
DE (1) DE60116109T2 (de)
ES (1) ES2253318T3 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658912B2 (en) * 2003-06-20 2010-02-09 University Of Massachusetts Spatial evolution of neural activity
BRPI0519111A2 (pt) * 2004-12-17 2008-12-23 Wyeth Corp mÉtodos para tratar o mal de parkinson, para melhorar um sintoma do mal de parkinson e para melhorar um sintoma de uma doenÇa ou distérbio cognitivos, e, uso de um ligando seletivo de erbeta
EP2024901A2 (de) 2006-05-25 2009-02-18 Elminda Ltd. Neuropsychologische räumlich-zeitliche mustererkennung
US20140214730A9 (en) * 2007-02-05 2014-07-31 Goded Shahaf System and method for neural modeling of neurophysiological data

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301143A1 (en) 1997-09-04 1999-03-11 The Regents Of The University Of California Differential ligand activation of estrogen receptors er.alpha. and er.beta. at ap1 sites
EP1021462A4 (de) 1997-10-07 2005-04-13 Merck & Co Inc Test für kernrezeptor-liganden unter verwendung von fret
AU2533499A (en) * 1998-02-12 1999-08-30 Prolifix Limited Interaction between cyclin d1 and steroid receptor co-activators and uses thereof in assays
CN1291102A (zh) * 1998-02-20 2001-04-11 耶拿制药两合公司 选择性替代中枢神经系统中雌激素缺乏的药物制剂
WO2000026232A1 (en) * 1998-11-04 2000-05-11 Board Of Trustees Of The University Of Illinois Repressor of estrogen receptor activity
HUP0104719A3 (en) 1998-12-18 2004-03-01 Wyeth Corp Bioassay for identifying estrogen receptor-betha/alfa selective modulators

Also Published As

Publication number Publication date
JP3754647B2 (ja) 2006-03-15
US7166438B2 (en) 2007-01-23
JP2003144192A (ja) 2003-05-20
DE60116109T2 (de) 2006-09-07
US20030087303A1 (en) 2003-05-08
EP1310799A1 (de) 2003-05-14
ES2253318T3 (es) 2006-06-01
EP1310799B1 (de) 2005-12-21
DE60116109D1 (de) 2006-01-26

Similar Documents

Publication Publication Date Title
DE602004021817D1 (de) Vorrichtung und verfahren zur repositionierung von patienten
EP1754707A3 (de) Multicyclische Verbindungen und deren Verwendung als Inhibitoren der PARP, VEGFR2 und MLK3 Enzyme
EA200501667A1 (ru) Рецепторный комплекс тканезащитных цитокинов, способы идентификации тканезащитных соединений и их применение
ATE266655T1 (de) Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
MA27853A1 (fr) LIGANDS DES RECEPTEURS DE CANNABINOiDES ET LEURS UTILISATIONS
MA27766A1 (fr) Ligands de recepteurs de cannabinoides et leurs utilisations
AP2002002620A0 (en) Substituted arylpyrazines
EA200600920A1 (ru) Иммуносорбентные исследования крови для оценки пароксизмальных церебральных разрядов
ITBO20020620A1 (it) Condotto multi-canale bioriassorbibile di rigenerazione del nervo e processo per preparare il medesimo.
ATE428719T1 (de) Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
EE04961B1 (et) N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis
DE60225899D1 (de) Ng atopischer dermatitis
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE313803T1 (de) In vitro screening nach liganden des östrogenrezeptors
DE60135482D1 (de) Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen
ATE425752T1 (de) Verwendung von pipamperon und einem sndri, snri oder ssri zur behandlung von stimmungs- oder angststírungen
DE602004032066D1 (de) Endocannabinoid-ähnliche Verbindungen und deren Verwendung zur Behandlung von Dermatitis
DE60211206D1 (de) Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden
DE602005013080D1 (de) Für prkcb1 kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung
CA2480429A1 (en) Novel therapeutical use of agonist ligands specific to g2a receptor
ATE460427T1 (de) Pleiotrophin wachstumfaktor rezeptor alk zur behandlung von proliferativen, gefässer- und neurologischen erkrankungen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
Serok Innovative applications of Gestalt therapy

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1310799

Country of ref document: EP

REN Ceased due to non-payment of the annual fee